Study Data from Sapporo Medical University Update Understanding of Diabetes (Mesenchymal stem cell therapy ameliorates diabetic hepatocyte damage in mice by inhibiting infiltration of bone marrow-derived cells)
By a News Reporter-Staff News Editor at Diabetes Week -- Data detailed on Diabetes have been presented. According to news reporting out of Sapporo, Japan, by NewsRx editors, research stated, "Although mesenchymal stem cells (MSCs) have been implicated in hepatic injury, the mechanism through which they contribute to diabetic liver disease has not been clarified. In this study, we investigated the effects of MSC therapy on diabetic liver damage with a focus on the role of bone-marrow-derived cells (BMDCs), which infiltrate the liver, and elucidated the mechanism mediating this process."
Our news journalists obtained a quote from the research from Sapporo Medical University, "Rat bone-marrow (BM)-derived MSCs were administered to high-fat diet (HFD)-induced type 2 diabetic mice and streptozotocin (STZ)-induced insulin-deficient diabetic mice. MSC-conditioned medium (MSC-CM) was also administered to examine the trophic effects of MSCs on liver damage. Therapeutic effects of MSCs were analyzed by assessing serum liver enzyme levels and histological findings. Kinetic and molecular profiles of BMDCs in the liver were evaluated using BM-chimeric mice. Curative effects of MSC and MSC-CM therapies were similar because both ameliorated the aggravation of aspartate aminotransferase and alanine aminotransferase at 8 weeks of treatment, despite persistent hyperlipidemia and hyperinsulinemia in HFD-diabetic mice and persistent hyperglycemia in STZ-diabetic mice. Furthermore, both therapies suppressed the abnormal infiltration of BMDCs into the liver, reversed excessive expression of proinflammatory cytokines in parenchymal cells, and regulated proliferation and survival signaling in the liver in both HFD-and STZ-diabetic mice. In addition to inducing hepatocyte regeneration in STZ-diabetic mice, both therapies also prevented excessive lipid accumulation and apoptosis of hepatocytes and reversed insulin resistance (IR) in HFD-diabetic mice. MSC therapy is a powerful tool for repairing diabetic hepatocyte damage by inhibiting inflammatory reactions induced by BMDCs and IR."
According to the news editors, the research concluded: "These effects are likely the result of humoral factors derived from MSCs."
For more information on this research see: Mesenchymal stem cell therapy ameliorates diabetic hepatocyte damage in mice by inhibiting infiltration of bone marrow-derived cells. Hepatology, 2014;59(5):1816-29. (Wiley-Blackwell - www.wiley.com/; Hepatology - onlinelibrary.wiley.com/journal/10.1002/(ISSN)1527-3350)
Our news journalists report that additional information may be obtained by contacting K. Nagaishi, Second Dept. of Anatomy, Sapporo Medical University, Sapporo, Japan. Additional authors for this research include K. Ataka, E. Echizen, Y. Arimura and M. Fujimiya (see also Diabetes).
Keywords for this news article include: Asia, Biotechnology, Japan, Sapporo, Diabetes, Proinsulin, Bone Marrow, Hepatocytes, Cell Therapy, Bone Research, Endocrinology, Immune System, Aminotransferase, Gastroenterology, Peptide Hormones, Biological Therapy, Stem Cell Research, Enzymes and Coenzymes, Mesenchymal Stem Cells.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC